Zhenping Zhu named co-CEO of Helixon

Zhenping Zhu joined Helixon as president and co-CEO. Zhu was previously president and CSO of 3SBio Inc. (HKEX:1530) and before that director general of China’s National Engineering Research Center for Antibody Drugs. Earlier in his career, he was president and CEO of Kadmon China and VP and global head of protein sciences and design at Novartis AG (SIX:NOVN; NYSE:NVS). Beijing-based Helixon, which is discovering protein therapeutics using AI, raised Rmb500 million in a series A round in January.

Allergy immunotherapies company ALK-Abello A/S (CSE:ALK B) hired Claus Sølje as EVP, CFO and board member, effective June 1, succeeding Søren Jelert, whose decision to leave the company was announced last November. Sølje held leadership roles for over 20 years at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), where he currently is SVP of international operations...